Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review
The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.
Abstract
Over the last decade, the discovery of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) has increased the treatment options for patients with type 2 diabetes mellitus (T2DM). GLP-1 RAs mimic the effects of native GLP-1, which increases insulin secretion, inhibits glucagon secretion, increases satiety and slows gastric emptying. This review evaluates the phase III trials for all approved GLP-1 RAs and reports that all GLP-1 RAs decrease HbA1c, fasting plasma glucose, and lead to a reduction in body weight in the majority of trials. The most common adverse events are nausea and other gastrointestinal discomfort, while hypoglycaemia is rarely reported when GLP-1 RAs not are combined with sulfonylurea or insulin. Treatment options in the near future will include co-formulations of basal insulin and a GLP-1 RA.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DUL is a long-acting GLP-1R agonist which can promote insulin secretion, inhibit gastric emptying, and reduce appetite. It is approved for treating hyperglycemia in patients with T2DM in many countries (105, 106).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [106]
Citations
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 1×
“reported significantly decreased postprandial plasma glucose (PPG) levels in the 5 and 10 μg exenatide groups compared with the placebo group.[15,16] In patients of Asian descent treated with oral antidiabetic agents, Gao et al.”
BackgroundBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 1×
“respectively, and minor hypoglycemic events were less frequent in the liraglutide group than in the exenatide group.[103]”
BackgroundBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346 · cited 6×
“[103] The DURATION-6 trial investigated EQW 2 mg headto-head with liraglutide 1.8 mg QD in patients treated with metformin, SU, TZD or a combination of these drugs for 26 weeks (baseline HbA1c 8.4–8.5%; BMI 32.3 kg/m2).”
BackgroundInfluentialGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 11×
“Meanwhile, the longer half-lives of the longer-acting GLP-1 RAs allow for greater effects on the total 24 h glucose level, including FPG.[6] This difference found among GLP-1 RAs is also evident in their varying efficacies with regard to HbA1c reduction and weight loss, as well as their differing tolerability profiles…”
BackgroundInfluentialKendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · cited 8×
“[103] The DURATION-6 trial investigated EQW 2 mg headto-head with liraglutide 1.8 mg QD in patients treated with metformin, SU, TZD or a combination of these drugs for 26 weeks (baseline HbA1c 8.4–8.5%; BMI 32.3 kg/m2).”
BackgroundInfluentialNauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · cited 3×
“Drucker, 2008 [72] Exenatide 2 mg QW 295 30 Met/SU/TZD or a combination −1.”
BackgroundResultGarber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057 · cited 2×
“5%).[49,50,55] The LEAD-1 trial found liraglutide 1.”
ResultVilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · cited 1×
“treatment period of 20 weeks.[12] Exenatide BID is subcutaneously administered before the morning and evening meals as 5 μg BID for the first four weeks of”
Method
Research works printed but not linked: 8
- American Diabetes Association, 2015, Diabetes Care, 38
- Lund A, 2014, Eur J Intern Med
- Robinson LE, 2013, BMJ Open, 3
- Mann KV, 2014, Diabetes Metab Syndr Obes Targets Ther, 7, 229
- Woodward HN, 2014, Patient Prefer Adherence, 8, 789
- Blair HA, 2015, Drugs
- 10.2337/dc09-0366 · DOI · Paper page
- Giorgino F, 2015, Diabetes Care
Cited by
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248
Mitchell, P. D., Salter, B. M., Oliveria, J. P., El‐Gammal, A., Tworek, D., Smith, S. G., Sehmi, R., Gauvreau, G. M., Butler, M., & O'Byrne, P. M. (2017) · Clinical & Experimental Allergy · doi:10.1111/cea.12860 · Cited by 78
Huang, S., Ma, S.-Y., Ning, M., Yang, W., Ye, Y., Zhang, L., Shen, J., & Leng, Y. (2019) · Metabolism · doi:10.1016/j.metabol.2019.07.003 · Cited by 65
Discovery of ecnoglutide - a novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog
Guo, W., Xu, Z., Zou, H., Li, F., Li, Y., Feng, J., Zhu, Z., Zheng, Q., Zhu, R., Wang, B., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101762 · Cited by 58
“In the last few years, dulaglutide and semaglutide have become available; these are long-acting GLP-1 analogs with >100hour half-lives and require once weekly injection [3,4].”
BackgroundWang, Q., Wang, J., Li, N., Liu, J., Zhou, J., Zhuang, P., & Chen, H. (2022) · Molecules · doi:10.3390/molecules27020444 · Cited by 63
Semaglutide seems to be more effective the other GLP-1Ras
Holst, J. J., & Madsbad, S. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.11.10 · Cited by 45
“As a drug class, the GLP-1RAs have proven efficacy for lowering HbA1c and decreasing weight in T2D, with a reduced risk of hypoglycaemia compared with insulin or sulphonylureas (1,2,23).”
BackgroundInfluentialSelf-citationYang, Z., Wang, Y., & Chen, S. (2020) · Journal of Functional Foods · doi:10.1016/j.jff.2020.104310 · Cited by 46
Madsbad, S., & Holst, J. J. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2472408 · Cited by 43
“GLP-1 RAs mimic the effects of native GLP-1, which increases insulin secretion, inhibits glucagon secretion, increases satiety, and slows gastric emptying [10,11].”
Self-citationPinho, A., Fortuna, A. C., Falcão, A. C., Paiva‐Santos, A. C., Seiça, R. M. F., Estevens, C., Veiga, F., & Ribeiro, A. J. (2019) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2019.02.001 · Cited by 41
Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists
Madsbad, S., & Holst, J. J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac112 · Cited by 39
Self-citationQin, L., Chen, S., Flood, E. M., Shaunik, A., Romero, B., de la Cruz, M., Alvarez, C., & Grandy, S. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0230-2 · Cited by 40
“Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a newer class of injectable T2DM treatments developed to target the incretin system [15, 16].”
BackgroundGlucagon-like peptide-1 receptor agonist stimulates mitochondrial bioenergetics in human adipocytes
Góralska, J., Śliwa, A., Gruca, A., Raźny, U., Chojnacka, M., Polus, A., Solnica, B., & Malczewska-Malec, M. (2017) · Acta Biochimica Polonica · doi:10.18388/abp.2017_1634 · Cited by 34
“GLP-1RAs mimic the effects of native GLP-1, which increases insulin secretion, inhibits glucagon secretion, increases satiety and slows gastric emptying (Østergaard et al., 2016).”
BackgroundUnlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
AL-Noshokaty, T. M., Abdelhamid, R., Abdelmaksoud, N. M., Khaled, A., Hossam, M., Ahmed, R., Saber, T., Khaled, S., Elshaer, S. S., & Abulsoud, A. I. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.101895 · Cited by 30
Jiang, H., Feng, S., Zhang, P., Wang, J., Jiang, Y., Zhang, H., Song, X., Huang, W., Xie, Y., & Deng, C. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118300 · Cited by 23
Ojo, O. O., Srinivasan, D. K., Owolabi, B. O., McGahon, M. K., Moffett, R. C., Curtis, T. M., Conlon, J. M., Flatt, P. R., & Abdel‐Wahab, Y. H. A. (2016) · Biological Chemistry · doi:10.1515/hsz-2016-0120 · Cited by 22
Harnessing GLP‐1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon
Abdelrahman, R. M., Musa, T. H., Arbab, I. A., Suliman, M. H., Ahmed, E. O., Mohamed, A. N., Musa, H. H., Jalal, M., & Gasmallah, S. I. (2025) · Journal of Obesity · doi:10.1155/jobe/9919810 · Cited by 24
Owolabi, B. O., Ojo, O. O., Srinivasan, D. K., Conlon, J. M., Flatt, P. R., & Abdel‐Wahab, Y. H. A. (2016) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-016-1243-5 · Cited by 18
“In the case of drugs based upon the structure of GLP1, this problem has been addressed by the design of analogues that incorporate a fatty acid moiety that facilitates binding to albumin and D-amino acids to increase stability to peptidases (Østergaard et al. 2016).”
InfluentialJoubert, M., Opigez, V., Pavlikova, B., Peyro Saint Paul, L., Jeandidier, N., Briant, A. R., Parienti, J., & Reznik, Y. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14225 · Cited by 13
“The effects of GLP-1RAs are obtained because of their multiple mechanisms of action, including stimulation of pancreatic insulin secretion but also suppression of pancreatic glucagon secretion, slowing of gastricemptying and reduction of food intake.(7) These latter two mechanisms, which are independent of insulin sec…”
BackgroundPyšná, J., Pyšný, L., Cihlář, D., Petrů, D., & Škopek, M. (2020) · Sustainability · doi:10.3390/su122310042 · Cited by 13
“Obesity, particularly visceral deposition of fat, also significantly increases the risk of type 2 diabetes mellitus [23,24].”
BackgroundWang, N., Yang, T., Li, J., & Zhang, X. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s202024 · Cited by 12
“Moreover, unlike GLP-1 receptor agonists, DPP4 inhibitors can be orally administered, do not reduce BW, and do not cause serious gastrointestinal adverse reactions.(19,20) Therefore, theoretically, combination of DPP4 inhibitors and insulin treatment may exert beneficial effects in T2DM patients compared to intensive…”
BackgroundIngves, S., Vilhelmsson, N., Ström, E., Fredrikson, M. G., Guldbrand, H., & Nyström, F. H. (2017) · Peptides · doi:10.1016/j.peptides.2017.04.011 · Cited by 11
“Indeed, GLP-1 analogues are already in use for treatment of type 2 diabetes, and these drugs reduce body weight and glucose levels [11].”
Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients
Madsbad, S. (2019) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2019.1615444 · Cited by 11
“ment program ‘Liraglutide Effect and Action in Diabetes’ (LEAD), completed in 2007 [5,21].”
BackgroundInfluentialSelf-citationAbdelrahman, R. M., Musa, T. H., Arbab, I. A., Ahmed, E. O., Gasmallah, S. I., Jalal, M., Mgbechidinma, C. L., & Ahmed, W. R. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100699 · Cited by 11
Treatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_20-1 · Cited by 9
Self-citationGudoor, R., Suits, A., & Shubrook, J. H. (2023) · Diabetology · doi:10.3390/diabetology4030032 · Cited by 8
“They mimic the effects of GLP-1, causing glucose-induced insulin secretion and the inhibition of glucagon secretion, and delaying gastric emptying, similar to DPP-4 inhibitors [32].”
ResultAbdelrahman, R. M., Sharif, S. I., Musa, T. H., Musa, H. H., Arbab, I. A., Suleiman, M. H., Mohammed, K. A. E., Gasmallah, S. I., Mgbechidinma, C. L., Jalal, M., et al. (2025) · Obesity Medicine · doi:10.1016/j.obmed.2025.100640 · Cited by 9
Alharbi, S., & Alkhalifah, A. (2026) · Skin Appendage Disorders · doi:10.1159/000550540 · Cited by 6
“Originally introduced for the treatment of type 2 diabetes mellitus, GLP-1 RAs mimic endogenous GLP-1 to enhance insulin secretion, delay gastric emptying, and suppress appetite [8].”
Glycaemic control and weight loss with semaglutide in type 2 diabetes
Madsbad, S., & Holst, J. J. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30094-3 · Cited by 7
Self-citationJi, W.-W., Yu, D., Fan, M., You, M., Lü, Y., Li, E.-B., Xie, N., & Yan, S. (2017) · Acta Diabetologica · doi:10.1007/s00592-017-0992-z · Cited by 3
“Glucagon-like peptide-1 (GLP-1) has become a hot therapeutic target for the treatment of patients with T2DM as GLP-1-based strategies have many advantages [4].”
BackgroundLubberding, A. F., Holst, J. J., & Madsbad, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00017-6 · Cited by 1
Self-citationDejgaard, T. F., & Madsbad, S. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12807 · Cited by 1
“Thirdly, gastrointestinal side effects were not evaluated, which is relevant in relation to drop-outs during treatment with a GLP-1RA.6 Another barrier to initiation of GLP-1RA treatment not discussed is the cost compared with insulin therapy, and obtaining reimbursement for initiation of GLP-1RA can be problematic.”
BackgroundResultInfluentialSelf-citationThe role of gut hormones on food intake and carbohydrate tolerance
Tharakan, G. (2016) · Spiral (Imperial College London) · doi:10.25560/41846
“long acting agonists at the PYY or OXM receptors, although these are in phase I development(279-281).”
BackgroundJoubert, M., & Reznik, Y. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30071-x
“In this setting, the current guidelines have proposed that GLP-1RAs be used in combination with insulin after specialist-care advice [3,4] in subjects who are more severely obese or in those who may lack the capacity to handle the complexities of a multiple daily injection (MDI) insulin regimen [1].”
BackgroundTreatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_20 · Cited by 1
Self-citationInfluence of fruit, meal distribution and dental health on cardio-metabolic risk
Ström, E. (2022) · Linköping University medical dissertations · doi:10.3384/9789179294489
Effect of GLP-1RA on blood eosinophil levels in adults: a real-world study
Wu, Y., Lin, Y. W., Wu, J., Zhao, L., Lin, Y. W., Chen, W., Zhu, Y., Wang, Y., Zhang, M., & Bao, W. (2026) · BMC Pulmonary Medicine · doi:10.1186/s12890-026-04469-8
“Semaglutide, a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist (GLP-1RA), is increasingly prescribed for patients with T2DM, particularly those who are overweight [10].”
Hwang, I., Lee, S. W., & Kim, Y. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s604247
“7,8 The efficacy of the GLP-1RA class is well-established in landmark clinical trials.”
Semaglutide and the Heart: Focus on Their Love–Hate Relationship
Khan, E., Fernandes, J., Gohel, V., Jain, R., Jayne, W., Peck, C., Shah, T. S., Shah, R. S., LaBarge, J., Ray, S. D., et al. (2026) · Hearts · doi:10.3390/hearts7030022
“Dulaglutide has a similar half-life to semaglutide of about a week, which is primarily due to its bulky size with protein addition which causes slower renal clearance [32].”
Abunada, S., Abunada, O., Vivek, F., Rathi, L., Muskan, F., Parkash, J., Nazeer, S., Anchal, F., Danial, F., Turesh, K., et al. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02250-9
“Longer-acting agents such as liraglutide (~ 13 h) allow once-daily use, whereas newer agents such as Semaglutide and Dulaglutide have half-lives exceeding 100 h, enabling once-weekly administration [4, 5].”
Metadata
- Authors
- Østergaard, L., Frandsen, C. S., & Madsbad, S.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Østergaard, L.
- Venue
- Expert Review of Clinical Pharmacology
- Publisher
- Informa UK Limited
- Published
- 2016-01-08
- Volume
- 9
- Issue
- 2
- Pages
- 241-265
- ISSN
- 1751-2433 (ISSN-L)
- 1751-2441
- OpenAlex
- W2220690107
- Cited by
- 38
- References
- 134
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 1 · 2023: 4 · 2022: 3 · 2020: 3 · 2019: 4 · 2018: 2 · 2017: 7 · 2016: 5
- FWCI
- 0.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Review of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, glucagon-like peptide-1, insulin secretion, glucagon inhibition, satiety, gastric emptying, HbA1c reduction, fasting blood glucose, weight loss, nausea, hypoglycemia
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Insulin Secretion, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Blood Glucose, Diabetes Mellitus, Type 2, Glucagon, Humans, Hypoglycemic Agents, Insulin, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.